INFO & CONTACTS:  +39 02 2390 1

Retrospective-Prospective Registry of Immune-Mediated Type 1 Diabetes in Solid Tumor Patients Treated with Immune Checkpoint Inhibitors

Phase: Observational, retrospective-prospective, pharmacological study

Principal Investigator: Dott.ssa Indini Alice

Main Facility: Oncologia medica melanomi

Drug: Farmaco ICIs (Immune Checkpoint Inhibitors)

Pathologies: Melanoma

This study aims to evaluate the clinical and oncological characteristics of patients who develop type 1 diabetes mellitus during treatment with immune checkpoint inhibitors (ICI-T1DM).

Immune checkpoint inhibitors (ICIs) are a widely used therapeutic strategy in the treatment of solid tumors. Their mechanism of action, based on stimulation of the immune system, can induce immune-related adverse events (irAEs), including endocrinopathies.

Among the rarer but clinically significant endocrinopathies is the onset of ICI-T1DM, characterized by significant long-term morbidity. This form, defined as immune-mediated diabetes, is considered more aggressive than classic type 1 diabetes. With improved survival rates and the expanding use of ICIs even in early-stage settings, adverse events such as ICI-T1DM are becoming increasingly significant and require special attention.

The primary objective of the study is to analyze the patterns of onset, clinical management, and progression of ICI-T1DM in patients with solid tumors treated with ICIs.

The primary endpoint is to evaluate the clinical, biochemical, and immunological characteristics of patients at the time of ICI-T1DM diagnosis.

Last update: 13/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe